PepCL: A replay-based continual learning framework for updating peptide-MHC models

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Understanding peptide-major histocompatibility complex (MHC) class I binding is critical for effective vaccine and immunotherapy design but is a combinatorially complex challenge for which prediction models have become essential. MHC ligands are typically identified at scale via untargeted mass spectrometry (MS), and this has built a strong base for peptide-MHC model training. However, MS incompletely captures the vast peptide-MHC space due to technical, sampling, and biological biases. Although recently developed experimental assays have queried such blind spots yielding complementary information, existing peptide-MHC predictors have not yet incorporated these orthogonal data and are not designed to be updated as new data are generated. Here, we introduce PepCL ( Pep tide-MHC C ontinual L earning), a continual learning framework for updating peptide-MHC predictors with new assay data while explicitly preserving prior MS knowledge. To enable PepCL, we also develop MHCPrime, a new state-of-the-art pan-allelic peptide-MHC prediction model, trained on publicly available MS data, that can be effectively updated under our framework. We demonstrate that PepCL allows MHCPrime to learn previously unseen, assay-specific information while preventing catastrophic forgetting that is typically observed with conventional fine-tuning. We evaluate PepCL and MHCPrime in a variety of biological contexts, including infectious disease and cancer, and show improved peptide-MHC prediction that transfers across alleles for broader applicability in clinical settings. Overall, our results establish PepCL as a flexible framework for extending the utility of peptide-MHC models by improving their predictive performance as immunopeptidomics assays continue to evolve and new data become available.

Article activity feed